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Specific protein 1 (Sp1), the first transcription factor to be isolated, regulates the expression of numerous genes
involved in cell proliferation, apoptosis, and differentiation. Recent studies found that an increase in Sp1
transcriptional activity is associated with the tumorigenesis. Moreover, post-translational modifications of Sp1,
including glycosylation, phosphorylation, acetylation, sumoylation, ubiquitination, and methylation, regulate Sp1
transcriptional activity and modulate target gene expression by affecting its DNA binding activity, transactivation
activity, or protein level. In addition, recent studies have investigated several compounds with anti-cancer activity
that could inhibit Sp1 transcriptional activity. In this review, we describe the effect of various post-translational
modifications on Sp1 transcriptional activity and discuss compounds that inhibit the activity of Sp1.Introduction
The transcription factor Sp1 (specificity protein 1) belongs
to the family of Sp/KLF (Krüppel-like factor) transcription
factors. It is the first transcription factor purified and
cloned from mammalian cells [1]. The human Sp1 gene
maps to 12q13.1 and encodes a protein of 785 amino
acids. The protein contains an N-terminal transactivation
domain, which recruits the basal transcriptional machin-
ery complex to the target promoter, and a C-terminal
DNA binding domain, which contains three Cys2His2-type
zinc finger DNA binding motifs required for recognizing
GC-rich (GGGGCGGGG) promoter sequences [2]. Sp1
regulates thousands of genes, such as those encoding vas-
cular endothelial growth factor (VEGF), p21CIP1/WAF1, 12
(S)-lipoxygenase, phosphatase 2A (PP2A), and Sp1 itself.
Thus, Sp1 is important for a variety of physiological pro-
cesses, including angiogenesis, cell cycle progression, in-
flammation, and senescence [3-6]. Dysregulation of Sp1 is
observed in many cancers and neurodegenerative disor-
ders. Sp1 gene knockout is embryonic lethal at the 11th
day of gestation [7].
Sp1 has been reported to affect the tumorigenesis of
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distribution, and reproduction in any mediumtarget genes, which include oncogenes and tumor sup-
pressor genes. A recent study demonstrated that both
single nucleotide polymorphism (SNP) 285 and SNP 309
in MDM2 (murine double mutant 2) are found in breast
cancer and can affect the binding of Sp1 to the MDM2
promoter [8]. In addition, the insulin-like growth factor
(IGF) system plays an important role in the biology of
breast cancer. A previous study revealed that caveolin-1
up-regulates IGF-1 receptor gene transcription in breast
cancer cells via Sp1- and p53-dependent pathways [9]. A
number of E2-responsive genes involved in nucleotide
biosynthesis and cell cycle progression are dependent on
estrogen receptor (ER)-α/Sp1 interactions [10]. Moreover,
it was reported that phytoestrogen regulation of the vita-
min D3 receptor promoter is regulated by Sp1. Finally,
in the presence of the estrogen receptor antagonist
ICI 182780, ER-α and histone deacetylases (HDACs) dis-
sociate from Sp1, resulting in increased histone acetyl-
ation and the induction of p21 expression [11,12]. In
lung cancer, we recently found that Sp1 accumulates
in the early stage and then declines in the late stage,
which is important for lung cancer cell proliferation and
metastasis. Sp1 was required for lung tumor growth but
it suppressed metastasis by inducing E-cadherin expres-
sion. The clinical implication of these results is that Sp1
inhibition is seemingly inappropriate for all patients with
lung cancer ranging from stage I to IV [13]. In addition,
the deregulation of DNA (cytosine-5-)-methyltransferase 1
(DNMT1) is associated with a gain in the transcriptionalntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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DNMT1 overexpression might result in the epigenetic
alteration of multiple tumor suppressor genes and ultim-
ately lead to lung tumorigenesis and poor prognosis [14].
The cytosolic phospholipases A2 (cPLA2) expression is
regulated by Sp1 and c-Jun in lung cancer cells [15]. In
colon cancer, HDAC inhibitors can induce cancer cell
apoptosis by activating Krüppel-like factor 4, and Sp1/
Sp3 can increase the apoptotic sensitivity of colon can-
cers to histone deacetylase inhibitors [16]. In addition to
the cancer types described here, Sp1 is implicated in
other cancer types and in tumorigenesis by mediating the
expression of many oncogenes [17-19].
Effects of post-translational modifications of Sp1 on its
transcriptional activity
The involvement of Sp1 in the development of various
cancer types is well known. The transcriptional activity
of Sp1 is modulated by post-translational modifications
that regulate Sp1 protein level, transactivation activity,
and DNA binding affinity [20]. Here, we describe theFigure 1 The schematic diagram illustrating that various modificationSp1 modifications and their effects on Sp1 transcrip-
tional activity as indicated in Figure 1.
Phosphorylation
There are 23 putative phosphorylation sites (from Phos-
phoSitePlusW) among the 785 amino acids of Sp1. Many
of these sites have been shown to positively or negatively
affect Sp1 transcriptional activity by modulating Sp1’s
DNA binding affinity, transactivation activity, or total
protein level in a manner dependent on the position of
the residue or the condition of the cell [20].
Effect on Sp1 DNA binding activity
Sp1 is phosphorylated at Ser59 by cyclin A-cyclin
dependent kinase (CDK). In in vitro and in vivo phos-
phorylation studies, cyclin A-CDK complexes can phos-
phorylate Sp1, and the phosphorylation site is located
within the N-terminal region of the protein [21]. The
DNA binding activity of Sp1 is elevated in cells overex-
pressing cyclin A [21]. How a phosphorylation site
located in the N-terminus of Sp1 affects the zinc fingers in Sp1 modulate its transcriptional activity.
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needs further studies. We recently reported that Sp1 is a
mitotic substrate of CDK1/cyclin B1 and is phosphory-
lated by CDK1/cyclin B1at Thr739. Phosphorylation of
Sp1 reduces its DNA-binding ability and facilitates the
chromatin condensation process during mitosis [22]. At
the end of mitosis and the beginning of interphase, Sp1
is dephosphorylated by PP2A and returned to the chro-
matin. These results indicate that cancer cells use CDK1
and PP2A to regulate the movement of Sp1 in and out
of the chromosomes during cell cycle progression. Sp1 is
also phosphorylated at Thr668 by casein kinase II (CKII)
to decrease its DNA binding activity. In addition, treat-
ment of K562 cells with okadaic acid increases Sp1
phosphorylation and inhibits its DNA binding activity,
suggesting that steady state levels of Sp1 phosphoryl-
ation are established by a balance between kinase and
phosphatase activities [23]. However, phosphorylation of
Sp1 at Thr668, Ser670, and Thr681 by protein kinase C
zeta (PKC-ζ) is required for Sp1-dependent platelet-
derived growth factor-D activation in response to angio-
tensin II [24]. Further studies are needed to explain why
the phosphorylation of Sp1 in this region has different
effects on Sp1 transcriptional activity.
Effect on Sp1 transactivation activity
Many of the phosphorylation sites shown in Table 1
could regulate the transcriptional activity of Sp1 by alter-
ing its interaction with other proteins, such as p300 and
HDACs, which can positively or negatively regulates the
Sp1 target genes.Table 1 Post-translational modification of Sp1
PTM Modified sites Modified enzymes Fun












Sumoylation Lys16 Sumo-1 Enh
Methylation ND ND Rec
Acetylation Lys703 P300 Rec
Glycosylation Leu56/57 ND Sp1
Ser612/641/698/702, Thr640 ND Reg
ND: non-determine.Effect on Sp1 protein stability
Recent studies have shown several phosphorylation sites
related to Sp1 protein stability. Sp1 is highly phosphory-
lated during mitosis. Phosphorylation of Sp1 by c-Jun N-
terminal kinase 1 (JNK1) at Thr278/739 is important for
the maintenance of Sp1 in daughter cells. JNK1 is also
highly activated during tumorigenesis and correlates
with Sp1 protein level. These results indicate that JNK1
activation is necessary to phosphorylate Sp1 and to
shield Sp1 from the ubiquitin-dependent degradation
pathway during mitosis in tumor cell lines [28]. In
addition, heat shock protein 90 (HSP90) can interact
with Sp1 during mitosis to alter the phosphorylation of
Sp1 at Thr278/739 by JNK1 and increase Sp1 protein
stability [39]. These results indicate that Hsp90 might
interact with JNK1 and stabilize it during mitosis, and
thereby enhance the phosphorylation of Sp1. Our recent
studies indicate that phosphorylation of Sp1 at Thr739
increases its stability by preventing interaction with
RING finger protein 4 (RNF4), thus shielding Sp1 from
proteasome-dependent degradation [33]. However, the
manner in which phosphorylated Sp1 is shielded from
interaction with RNF4 needs to be clarified.
In addition, several phosphorylation sites of Sp1 have
been probed, and their roles have been elucidated, but
the detailed mechanism is still unknown. It was reported
that Sp1 can be phosphorylated by ataxia telangiectasia
mutated (ATM) at Ser101 under DNA damage condi-
tions [25]. Sp1 with a Ser101Ala mutation is not signifi-
cantly phosphorylated in response to damage, and it can
not restore sensitivity to DNA damage [25]. Thesections Ref.
ease Sp1 DNA binding activity [21]
lve in DNA damage and repair [25]
egulate expression of the HIV-1 Tat protein. [26]
ease expression of apolipoprotein A-I [27]
ease Sp1 protein stability [28]
ance VEGF expression [29]
ress PDGFR-α transcription [30]
bit RECK expression and promote cell invasion [31]
ease luteinizing hormone receptor (LHR) transcription [32]
reased Sp1 DNA binding acticity [23]
ease PDGF transcription [24]
rease Sp1 binding activity [22]
ance Sp1 degradation [33,34]
ruit Suv39H1 and HDAC1 to induce chromatin remodeling [35]
ruit HDAC1 and p300 to the promoter of the 12(S)-lipoxygenase [36]
degradation [37]
ulate transcriptional activity of Sp1 [38]
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a role in the cellular response to DNA damage. Ser101
phosphorylation did not affect transcriptional activity
from the Sp1 responsive promoter, but it did promote
co-localization of Sp1 with ATM phosphorylated at
Ser1981. These observations suggest that Sp1 phos-
phorylated at Ser101 might play a role in DNA repair at
damage sites rather than functioning in transcriptional
regulation, but further evidence is required to substanti-
ate this possibility. The mechanism by which Sp1, phos-
phorylated at Ser101 by ATM, affects DNA damage
needs to be elucidated. In addition, it was reported that
EGF stimulation of apoA-I expression is mediated solely
by the Ras-MAP kinase cascade and that enhanced
activity of this pathway requires Sp1 with an intact phos-
phorylation site at Thr266 [27]. It was also shown that
trichostatin A (TSA) causes marked phosphorylation of
Sp1 at Ser 641 by PKCζ in JAR and MCF-7 cells, indica-
ting that phosphorylation of Sp1 by phosphatidylino-
sitol 3-kinase (PI3K)/PKCζ is critical for TSA-activated
lutropin/choriogonadotropin receptor (LHR) gene ex-
pression [32]. It was also reported that p42/p44 mitogen-
activated protein kinase (MAPK) directly phosphorylates
Sp1 at Thr453 and Thr739 in vitro and in vivo, and
mutation of these sites to alanine decreases Sp1 transcrip-
tional activity [29]. In addition, fibroblast growth factor 2
(FGF-2) stimulates Sp1 phosphorylation in an extracellular
signal-regulated kinase (ERK) 1/2- but not p38-dependent
manner, and enhances Sp1 recruitment to the platelet-
derived growth factor receptor alpha (PDGFR-α) promoter
region [30]. It was also found that Sp1, phosphorylated
at Thr453 and Thr739 by ERK, binds preferentially to the
reversion-inducing cysteine-rich protein with Kazal motifs
(RECK) promoter, and then recruits HDAC1 to silence
RECK gene expression [31]. According to these studies,
phosphorylation at Thr453 and Thr739 by ERK1/2 in
interphase might modulate the transactivation activity of
Sp1. Taken together, the results suggest that phosphoryl-
ation of Sp1 at Thr739 is very important. In interphase
cells, it affects Sp1 transcriptional activity by modulating
different regulatory factors, such as HDAC1. In mitotic
cells, Thr739 phosphorylation controls the movement
of Sp1 in and out of chromosomes to finish chromosome
packaging by decreasing Sp1 DNA binding affinity.
Finally, it stabilizes Sp1 by shielding it from interaction
with RNF4.
Sumoylation and ubiquitination
Sumoylation is a post-translational modification involved
in various cellular processes such as nuclear-cytosolic
transport, transcriptional regulation, protein stability,
DNA repair, and apoptosis [40-44]. Sp1 can be sumoy-
lated by SUMO-1 at Lys16. Sumoylation of Sp1
decreases its protein stability by altering its subcellularlocalization and recruiting regulatory particle tripho-
sphatase 6 (RPT6) to increase ubiquitination. The
sumoylation level of Sp1 is decreased in tumorous cer-
vical tissues. These results suggest that Sp1 accumula-
tion correlates with the inhibition of sumoylation during
tumorigenesis [34]. In our recent study, we found that
RNF4 acts as the E3 ubiquitin ligase and triggeres Sp1
sumoylation and ubiquitin-mediated proteolysis [33].
Acetylation
Acetylation of histones, especially histone H3 and H4, is
important for gene regulation [45]. Recently, several
important non-histone proteins, such as p53 and Sp1,
were reported to be acetylated [36,46,47]. We found that
phorbol 12-myristate 13-acetate (PMA) induces the dea-
cetylation of Sp1, and then increases Sp1 transcriptional
activity at a target gene, 12(S)-lipoxygenase, by enhan-
cing the recruitment of p300 to the promoter of 12(S)-
lipoxygenase [36].
Methylation
Methylation, a common histone modification, negatively
affects gene expression by recruiting suppressor factors
such as HDACs or DNA methyltransferases [48]. Recently,
the functional activity of several important transcription
factors was found to be modified by methylation [49,50].
We recently found that methylated Sp1 recruits Suv39H1
and HDAC1 to the promoter of Sp1 target genes to re-
press gene expression [35]. However, the enzyme that pro-
vides the methyltransferase activity and the residue(s) that
is methylated are still unknown.
Glycosylation
Many important transcription factors, including Sp1, a key
promoter required for an optimal HSP response following
stress, are glycosylated by the O-GlcNAc pathway [51].
Previous studies indicated that heat shock factor-1,
HSP70, and HSP27 expression all rely on Sp1 binding to
their promoter regions [52-54]. Exposure of either cell line
to high-dose glutamine is sufficient to induce Sp1 glycosy-
lation and regulation of its target genes, such as arginino-
succinate synthetase [55]. However, under glucose
starvation, stimulation with cyclic AMP (cAMP) results in
nearly deglycosylation of Sp1, and Sp1 is rapidly proteo-
lytically degraded by an enzyme that can be inhibited by
specific proteasome inhibitors, lactacystin and N-acetyl-L-
leucyl-L-leucyl-L-norleucinal (LLnL) [56]. It was reported
that the chloride channel-2 (ClC-2) is induced by highly
phosphorylated and highly glycosylated Sp1 [57]. In
addition, high glucose (HG) concentrations can potentially
stimulate the expression of genes associated with the de-
velopment of diabetic nephropathy [58]. A recent report
also indicated that insulin dynamically regulates calmodu-
lin gene expression by sequential O-glycosylation and
Table 2 Compounds affected Sp1
Drugs Effect on Sp1 Cancer type Ref.
Oldenlandia Diffusa (OD) Positive Breast cancer [61]
Arsenic trioxide Negative Bladder cancer [62]
Celecoxib Negative Pancreatic cancer [63]
Bortezomib Negative Acute myeloid leukemia [64]
Curcumin Negative Bladder cancer [65]
GT-094 Negative Colon cancer [66]
3,30-diindolylmethane (DIM) Positive Breast cancer [67]
Indole-3-carbinol (I3C) Negative Breast cancer [68]
Trichostatin A (TSA) Positive Hepatoma [69]
Tolfenamic Acid Negative Pancreatic cancer [70]
Mithramycin A Negative ND [71]
Betulinic acid Negative Prostate and lung cancer [72,73]
ND: non-determine.
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hyperglycemia-induced mitochondrial superoxide over-
production increases hexosamine synthesis and O-glycosy-
lation of Sp1, which activates the expression of genes that
contribute to the pathogenesis of diabetic complications
[60]. According to previous studies, there is a good correl-
ation between glycosylation and phosphorylation of Sp1.
Cross-talk between phosphorylation and glycosylation
requires further investigation.
Compounds inhibiting Sp1 transcriptional activity
Sp1 accumulates in most of cancer types and partici-
pates in their tumorigenesis. Several compounds with
anti-tumor effects act by inhibiting Sp1 transcriptional
activity as indicated in Table 2. A previous study found
that Oldenlandia diffusa (OD) extracts strongly inhibit
anchorage-dependent and -independent cell growth and
induced apoptosis in ERα-positive breast cancer cells,
and increase p53 expression as a result of enhanced
binding of the ERα/Sp1 complex to the p53 promoter
region [61]. Arsenic trioxide downregulates Sp1 expres-
sion and Sp-dependent gene expression in bladder can-
cer [62]. Celecoxib treatment reduces both Sp1 DNA
binding affinity and its transactivating activity in pancre-
atic cancer [63]. Bortezomib decreases Sp1 protein
levels, disrupts the interaction of Sp1 with NF-kappaB,
and prevents binding of the Sp1/NF-kappaB complex to
the DNMT1 gene promoter for repression in acute mye-
loid leukemia [64]. Curcumin was reported to induce
proteasome-dependent degradation of Sp protein in
bladder cancer [65]. GT-094 could downregulate Sp ex-
pression, and then repress Sp-regulated genes in colon
cancer [66]. Treatment with 3,30-diindolylmethane
(DIM) could induce Sp1-mediated p21 expression in
breast cancer cells [67]. Indole-3-carbinol (I3C) inhibits
Sp1-mediated CDK6 expression in breast cancer [68].Trichostatin A (TSA) treatment could increase Sp1-
mediated IGF binding protein 3 (IGFBP-3) promoter ac-
tivity in hepatoma [69]. Tolfenamic acid treatment
induces the degradation of Sp1, Sp3, and Sp4 in pancre-
atic cancer [70]. Mithramycin A, the G-C specific DNA-
binding drug, could bind to both consensus sequences
and then prevent subsequent Sp1 binding to repress
Sp1-mediated target gene expression [71]. Betulinic acid
(BA) was reported to induce Sp1 degradation in prostate
cancer [72]. Our recent study also indicates that BA
could induce the sumoylation of Sp1 and then recruit
the E3 ubiquitin ligase, RNF4, which contains SUMO-
interacting motifs, to increase Sp1 ubiquitination, lead-
ing to Sp1 degradation in lung cancer [73].Perspective
Although many studies have addressed the importance
of Sp1 in tumorigenesis, much about Sp1 is still un-
known. First, many post-translational modifications have
been identified, but the cross-talk between these modifi-
cations needs further studies. Second, although many
functions have been described, the relationship between
Sp1 function and structure remains unknown. This may
be due to instability of the Sp1 protein. Finally, a grow-
ing number of compounds inhibit Sp1 and suppress
tumor formation, but a detailed mechanism and the side
effects require further clarification.
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